Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q2 EPS of $0.00, $0.01 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $40.2 million versus the consensus estimate of $39.63 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.